CONNEQT US pharma customer comes back for more

详细摘要
CQT has secured another $340,000 from a US pharmaceutical customer, lifting the value of its cardiovascular clinical trial contract 33% ... Read More The post CONNEQT US pharma…
CONNEQT has received a healthy boost with a US drug trial growing by 50%. Pic: Getty Images
Special Report: CONNEQT Health has secured more work from a US drug developer after the customer expanded a Phase 2b cardiovascular clinical trial from 30 to 45 investigational sites.
The amendment adds US$240,000 (~$340,000) to the agreement, taking its total value for CONNEQTHealth (ASX:CQT) to US$950,000 ($1.36 million).
The customer, a privately owned US biopharmaceutical company, is developing treatments for hypertension and other serious cardiovascular diseases.
Announced in October 2025, the original contract covered 30 US trial sites. The latest expansion follows the addition of a second study visit to the trial protocol, with CONNEQT’s wholly owned subsidiary ATCOR Medical providing the equipment and associated services.
CONNEQT CEO Craig Cooper said the amendment was an endorsement of the company’s delivery and technology.
“The expansion of this trial from 30 to 45 sites is a strong endorsement of our team’s delivery and of SphygmoCor’s role in generating reliable cardiovascular endpoints. It reflects the growing demand from pharmaceutical sponsors for our vascular assessment platforms and services,” Cooper said.
ATCOR will supply another 15 SphygmoCor XCEL systems and 30 Oscar 2 ambulatory blood pressure monitors, taking the total equipment commitments under the agreement to 45 and 90 respectively.
The additional equipment will be leased for about seven months. ATCOR will also handle configuration, virtual operator training and certification, technical support and data management.
文章开头,摘自Stockhead。如需阅读全文,请前往媒体网站。
MarketNews 仅展示媒体发布的标题和摘要,全文请在出版方网站阅读。 (stockhead.com.au)




